The Study on the drug pharmacokinetics according to the progression of liver disease

  • Sohn, Soo-Jung (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University) ;
  • Choi, Hong-Serck (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University) ;
  • Ahn, Mee-Ryung (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University) ;
  • Chung, Hye-Joo (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University) ;
  • Yoo, Tae-Moo (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University) ;
  • Lee, Min-Ho (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University) ;
  • Park, Moon-Seung (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University) ;
  • Shin, In-Chul (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University) ;
  • Kim, Ju-ll (National Institute of Toxicological Research, KFDA.&College of Medicine, Hanyang University)
  • Published : 2003.04.01

Abstract

We underwent this study to know correlation between the amount of portosysternic shunt/hepatic fibrosis and bioavailability parameters such as AUC, Cmax, Tmax and t1 /2 of high extraction ratio drug, propranolol, in CCl4-induced liver cirrhosis model of rats. This study describes the bioavaility study of propranolol(5 mg/kg), Shunt Index using thallium-201 per rectum scintigraphy to to measure the amount of portosystemic shunt indirectly and intrahepatic hydroxyproline content performed in the CCl4-induced liver cirrhosis model of rats. (omitted)

Keywords